US2022175906A1PendingUtilityA1

Zika virus rna vaccines

69
Assignee: MODERNATX INCPriority: Sep 14, 2017Filed: Nov 19, 2021Published: Jun 9, 2022
Est. expirySep 14, 2037(~11.1 yrs left)· nominal 20-yr term from priority
Inventors:Giuseppe CiaramellaSunny Himansu
Y02A50/30A61K 39/12A61K 2039/575A61P 31/14A61K 48/005A61K 2039/55555A61K 2121/00A61K 2039/53A61K 2039/545C12N 2770/24134A61K 47/6931A61K 2039/525A61K 31/7088A61K 9/51A61K 2039/54
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein, in some embodiments, are Zika virus RNA vaccines and methods of producing an antigen-specific immune response in a subject.

Claims

exact text as granted — not AI-modified
1 . A method comprising administering to a subject a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a Japanese encephalitis virus (JEV) signal peptide fused to a Zika virus (ZIKV) prME protein comprising a sequence having at least 90% identity to SEQ ID NO: 7, wherein the mRNA is in a composition comprising a lipid nanoparticle. 
     
     
         2 - 38 . (canceled) 
     
     
         39 . The method of  claim 1 , wherein 20 μg-200 μg of the mRNA is administered to the subject. 
     
     
         40 . The method of  claim 39 , wherein 20 μg-60 μg of the mRNA is administered to the subject. 
     
     
         41 . The method of  claim 1 , wherein a first dose and a second dose of the mRNA is administered to the subject. 
     
     
         42 . The method of  claim 1 , wherein the ZIKV prME protein comprises a sequence having at least 95% identity to SEQ ID NO: 7. 
     
     
         43 . The method of  claim 42 , wherein the ZIKV prME protein comprises the sequence of SEQ ID NO: 7. 
     
     
         44 . The method of  claim 1 , wherein the mRNA vaccine comprises at least one modified nucleotide. 
     
     
         45 . The method of  claim 44 , wherein at least 80% of uracil nucleotides in the ORF of the mRNA have a 1-methyl-pseudouridine modification. 
     
     
         46 . The method of  claim 45 , wherein 100% of uracil nucleotides in the ORF of the mRNA have a 1-methyl-pseudouridine modification. 
     
     
         47 . The method of  claim 1 , wherein the lipid nanoparticle comprises 20-60 mol % ionizable cationic lipid, 5-25 mol % non-cationic lipid, 25-55 mol % sterol, and 0.5-15 mol % PEG-modified lipid. 
     
     
         48 . The method of  claim 47 , wherein the ionizable cationic lipid comprises the following compound: 
       
         
           
           
               
               
           
         
       
     
     
         49 . A method comprising:
 administering to a subject a first dose and a second dose of a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a Japanese encephalitis virus (JEV) signal peptide fused to a Zika virus (ZIKV) prME protein comprising a sequence having at least 95% identity to SEQ ID NO: 7, wherein the mRNA is in a composition comprising a lipid nanoparticle.   
     
     
         50 . The method of  claim 49 , wherein 20 μg-60 μg of the mRNA is administered to the subject. 
     
     
         51 . The method of  claim 49 , wherein at least 80% of uracil nucleotides in the ORF of the mRNA have a 1-methyl-pseudouridine modification. 
     
     
         52 . The method of  claim 51 , wherein 100% of uracil nucleotides in the ORF of mRNA have a 1-methyl-pseudouridine modification. 
     
     
         53 . The method of  claim 49 , wherein the lipid nanoparticle comprises 20-60 mol % ionizable cationic lipid, 5-25 mol % non-cationic lipid, 25-55 mol % sterol, and 0.5-15 mol % PEG-modified lipid. 
     
     
         54 . The method of  claim 53 , wherein the ionizable cationic lipid comprises the following compound: 
       
         
           
           
               
               
           
         
       
     
     
         55 . A method comprising:
 administering to a subject a first dose and a second dose of a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a Japanese encephalitis virus (JEV) signal peptide fused to a Zika virus (ZIKV) prME protein comprising a sequence having at least 95% identity to SEQ ID NO: 7, wherein 100% of uracil nucleotides in the ORF of mRNA have a 1-methyl-pseudouridine modification, and wherein the mRNA is in a composition comprising a lipid nanoparticle, and wherein 20 μg-60 μg of the mRNA is administered to the subject.   
     
     
         56 . The method of  claim 55 , wherein the lipid nanoparticle comprises 20-60 mol % ionizable cationic lipid, 5-25 mol % non-cationic lipid, 25-55 mol % sterol, and 0.5-15 mol % PEG-modified lipid. 
     
     
         57 . The method of  claim 56 , wherein the ionizable cationic lipid comprises the following compound:

Join the waitlist — get patent alerts

Track US2022175906A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.